Octoplus Terug naar discussie overzicht

Octoplus koopt rechten van Isotis

1. [verwijderd] 25 april 2007 08:29

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   RTRS-Octoplus koopt rechten van Isotis
   LEIDEN (ANP) - Biotechnologiebedrijf Octoplus heeft
   patentrechten gekocht van branchegenoot Isotis. Dat heeft
   Octoplus woensdag bekendgemaakt.
   
   Het gaat om additionele patenten op een technologie, genaamd
   Polyactive, die Octoplus gebruikt voor het maken van bepaalde
   geneesmiddelen. Octplus gebruikt de technologie onder meer in
   zijn belangrijkste product LocteronTM, een middel voor de
   behandeling van chronische Hepatitis C.
   
   Octplus betaalt een licentiebedrag van 1,25 miljoen euro aan
   Isotis om gebruik te maken van de technologie. Volgens de
   onderneming verminderen hierdoor de toekomstige betalingen voor
   het gebruik van Polyactive.
   
   ((ANP Redactie Economie, email economie(at)anp.nl, +31 20
   504 5999))
   
2. pim f 25 april 2007 09:36

   auteur info

   • pim f

     Lid sinds: 29 sep 2004

     Laatste bezoek: 31 mrt 2025

   • Aanbevelingen

     Ontvangen: 874

     Gegeven: 783

   •    Aantal posts: 4.111

   OctoPlus koopt rechten op PolyActive technologie van IsoTis
   
   AMSTERDAM (Dow Jones)--OctoPlus nv heeft de additionele patenten op de PolyActive technologie, voor de afgifte van geneesmiddelen, gekocht van IsoTis inc. Dit meldt het biotechnologiebedrijf woensdag voorbeurs.
   
   OctoPlus gebruikt PolyActive in zijn stermedicijn Locteron, een geneesmiddel voor de behandeling van chronische hepatitis C, dat momenteel wordt getest in een Fase IIa onderzoek.
   
   Het bedrijf uit Leiden krijgt met de overeenkomst op bepaalde strategische gebieden de volledige rechten op de technologie en het bijbehorende intellectuele eigendom van PolyActive, waaronder op verdere toepassingen op het gebied van de orthopedie. Daarnaast heeft het contract financiele voordelen door de betaling van een licentiebedrag van EUR1,25 miljoen, waardoor toekomstige betalingen over OctoPlus' inkomsten door gebruik van PolyActive verminderen.
   
   Door Marjolein Timmer; Dow Jones Nieuwsdienst; +31-20-5890270; marjolein.timmer@dowjones.com
   
   
   
3. [verwijderd] 25 april 2007 17:22

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Volgens mij betekent dit dat de volgende fase lla al positief word bevonden.
   
   Anders doe je niet zo'n aankoop
   
   Dit is volgens mij samen met het lex systeem ,
   om aardige voorraden aan te maken als locteron op de markt komt.
   
   gr zenzoe
4. [verwijderd] 25 april 2007 17:29

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   
   ANNUAL REPORT
   Access OctoPlus' Annual Report 2006 in PDF and interactive online version
   
   OCTO SHARE PRICE
   LATEST NEWS
   OctoPlus to present at London Biotech Investment Forum
   
   DOWNLOAD CENTER
   Click here to download our factsheets
   
   JOB OPENINGSAbout OctoPlus
   - Company profile
   - Mission statement
   - Contact
   Job opportunities
   - Introduction
   - Job listing
   - Application e-form
   Products
   - Overview
   - Locteron
   - OP-145
   - Growth hormone
   - Japanese encephalitis vaccine
   - Hepatitis B vaccine
   Drug delivery
   - Overview
   - OctoDEX™
   - PolyActive™
   - SynBiosys™
   - Vaccine delivery
   Contract development
   - Overview
   - Formulation development
   - Clinical manufacturing
   Corporate information
   - Management
   - Supervisory board
   - Scientific advisory board
   - Corporate partners
   News centre
   - Latest news
   - News releases
   - Events
   - Newsletters
   - Download factsheets
   Investor relations
   - IPO Prospectus
   - Corporate governance
   - Financial information
   - Share price information
   - Financial calendar
   - Press releases
   - Investor relations contact
   HOME CONTACT April 25, 2007Home > Drug delivery > PolyActive™
   
   POLYACTIVE™
   PolyActive™ is a biodegradable polymeric drug delivery system
   
   Its biodegradability, extensive safety record and linear release properties make PolyActive™ an excellent technology for the controlled release of proteins and lipophilic small molecules.
   
   Products based on PolyActive™ can be used for both local and systemic administration, and have applications in pharmaceutics and medical technology.
   
   Key attributes of the PolyActive™ drug delivery system are:
   
   Suitable to encapsulate both small- and macromolecules
   Controllable, including linear, release profiles
   Low initial release: no burst
   Strong in vitro - in vivo correlation
   Well-preserved compound stability and activity
   Biodegradable and biocompatible
   Systemic and local applications
   Extensive biological safety file
   FDA approval and CE mark for medical devices
   Patent protected
   Partner with OctoPlus for drug delivery with PolyActive™
   OctoPlus is actively pursuing new partnerships to develop products based on the PolyActive™ delivery system. As a medium sized organisation, we are flexible in constructing partnership agreements and are open to take on some of the risk and cost for the development of promising compounds. Our priority is to build successful long-term drug delivery partnerships. Please feel free to contact us and discuss your ideas.
   
   OctoPlus' hepatitis C product Locteron™ is based on PolyActive™ technology.
   
   For more information on OctoPlus' PolyActive™ drug delivery technology, please download our PolyActive™ factsheet.
   
   
5. [verwijderd] 25 april 2007 17:31

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   My NCBI
   [Sign In] [Register]
   
   
   All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
   
   Search PubMed Protein Nucleotide CoreNucleotide GSS EST Structure Genome Books CancerChromosomes Conserved Domains dbGaP 3D Domains Gene Genome Project GENSAT GEO Profiles GEO DataSets HomoloGene Journals MeSH NCBI Web Site NLM Catalog OMIA OMIM PMC PopSet Probe Protein Clusters PubChem BioAssay PubChem Compound PubChem Substance SNP Taxonomy ToolKit UniGene UniSTS for
   
   
   Limits Preview/Index History Clipboard Details
   
   
   
   
   
   Note: Performing your original search, polyactive, in PubMed will retrieve 50 citations.
   
   Display Summary Brief Abstract AbstractPlus Citation MEDLINE XML UI List LinkOut ASN.1 Related Articles Cited Articles Cited in Books CancerChrom Links Domain Links 3D Domain Links GEO DataSet Links Gene Links Gene (GeneRIF) Links Genome Links Project Links GENSAT Links GEO Profile Links HomoloGene Links Nucleotide Links Nucleotide (RefSeq) Links OMIA Links OMIM (calculated) Links OMIM (cited) Links BioAssay Links Compound Links Compound via MeSH Substance Links Substance via MeSH Substance (Publisher) Links PMC Links Cited in PMC PopSet Links Probe Links Protein Links Protein (RefSeq) Links Protein Cluster Links SNP Links Structure Links Taxonomy via GenBank UniGene Links UniSTS Links Show 5 10 20 50 100 200 500 Sort by Pub Date First Author Last Author Journal Send to Text File Printer Clipboard E-mail Order
   
   
   All: 1 Review: 0
   
   
   
   
   1: J Biomed Mater Res. 2002 Mar 5;59(3):535-46. Links
   Biomimetic calcium phosphate coatings on Polyactive 1000/70/30.Du C, Klasens P, Haan RE, Bezemer J, Cui FZ, de Groot K, Layrolle P.
   IsoTis N V, Professor Bronkhorstlaan 10, 3723 MB Bilthoven, The Netherlands. chang.du@isotis.com
   
   Precalcification of Polyactive 1000/70/30 with a biomimetic calcium phosphate coating is expected to enhance the bioactivity of this biodegradable polymer for the application as bone filler or scaffold of bone tissue engineering. This study presents a 1-day one-step incubation method to obtain either amorphous or bone-like apatitic calcium phosphate coating on Polyactive 1000/70/30. Either dense plates or three-dimensional porous blocks of the polymer were incubated in a simplified but concentrated simulated body fluid-derived solution at 37 degrees C. By bubbling CO2 gas, a solution was prepared with calcium and phosphate ion concentrations five times of that of regular simulated body fluid. With controlled stirring, the CO2 was released out of the solution and exchanged by air. The pH of the solution increased to induce coating formation. Adjusting stirring rate and CO2/air exchange rate controlled the process kinetics. The reaction kinetics had little influence on the crystallographic structure of the final coating mineral for a given solution composition as shown by Fourier transform infrared spectroscopy and X-ray diffraction. However, the interface structure between the coating and substrate was kinetics-dependent. A fast precipitation condition resulted in a uniform but superficial calcification pattern at the surface of polymer. A slow process by selecting either a slow stirring or a slow CO2/air exchange, on the contrary, induced a localized but deep inside calcification pattern. A tensile test showed no statistically significant difference in the mechanical properties among uncoated and coated polymers. The cracking behavior of coatings from different kinetics, however, exhibited different manners, as can be attributed to different interface structures and interfacial strengths. Copyright 2001 John Wiley & Sons, Inc.
   
   PMID: 11774312 [PubMed - indexed for MEDLINE]
   
   
6. [verwijderd] 27 april 2007 14:03

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Als we zien wat IsoTis doet dan zie je Octoplus langzaam stijgen. De verwachting is ook dat deze trend zich doorzet. De bewegingen in biotechnologische- en farmaceutische bedrijven rechtvardigen dit "gevoel". Een redelijk kansrijk aandeel dus.
7. [verwijderd] 27 april 2007 14:26

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   FredNomos schreef:

   Als we zien wat IsoTis doet dan zie je Octoplus langzaam stijgen. De verwachting is ook dat deze trend zich doorzet. De bewegingen in biotechnologische- en farmaceutische bedrijven rechtvardigen dit "gevoel". Een redelijk kansrijk aandeel dus.
   

   dit is een hele slechte vergelijking als je weet dat isotis van 12 euro afkomt door fda kwestie.isotis is gewoon aan het herstellen.
8. [verwijderd] 27 april 2007 16:35

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Snap ik. Maar volg de geruchtenstroom maar eens op Nasdaq.
9. [verwijderd] 27 april 2007 17:09

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   heb je een link naar deze geruchtenstroom?
10. [verwijderd] 23 mei 2007 12:58

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Isotis +20% ?
11. [verwijderd] 12 juli 2007 23:44

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    SurModics and Paragon Intellectual Properties to Collaborate on FINALE(TM) Coated Prohealing Stent to Combat Late Stent Thrombosis
    
    SurModics Invests $3.5 Million in Paragon and Its Newly Formed Subsidiary
    
    EDEN PRAIRIE, Minn. & CHARLESTON, W. Va.--(HSMN NewsFeed)--SurModics, Inc. (Nasdaq:SRDX ) and Paragon Intellectual Properties, LLC announced today the signing of a license agreement under which the companies will collaborate on the development of a novel stent system for the treatment of coronary artery disease. The stent system, which incorporates SurModics' proprietary FINALE(TM) Prohealing coating technology and Paragon's unique low-profile coronary stent system, is designed to address late stent thrombosis, a serious complication occurring in a small percentage of coronary stent cases.
    
    In addition, SurModics announced that it has made a $3.5 million equity investment in Paragon and its newly formed subsidiary, Apollo Therapeutics, LLC. SurModics has agreed to invest an additional $2.5 million upon successful completion of specified development milestones.
    
    "Late stent thrombosis is a rare but potentially devastating complication associated with coronary stents," said Mark C. Bates, M.D., CEO of Paragon and Apollo and a leading interventional cardiologist and founder of the CAMC Vascular Center of Excellence in Charleston, West Virginia. "We firmly believe that SurModics' FINALE prohealing coating technology will speed recovery of the normal vessel architecture and inner cell lining, with the potential to not only eliminate late thrombosis but also reduce restenosis. By combining this innovative technology with Paragon's low-profile stent system, we move closer to the panacea of a highly deliverable coronary stent with a biologic coating that has the efficacy of a drug eluting stent without the long-term concern of late stent thrombosis."
    
    "We are very pleased to team up with Paragon and Apollo on this exciting new development effort," said Bruce Barclay, President and CEO of SurModics. "We were extremely encouraged by the results our FINALE prohealing coating technology produced in preclinical studies. I have had the pleasure of working with Dr. Bates in the past, and his network of clinical contacts and strong record in product innovation will be significant assets in our joint development efforts. In addition, Apollo's novel stent design and strong engineering talent nicely complement our coating and development expertise. We believe Dr. Bates and his colleagues are the right team to rapidly carry this technology into the clinic. We are delighted to have signed the first stent license incorporating our FINALE prohealing coating technology, and look forward to collaborating with the Paragon and Apollo teams to accelerate the commercialization of this exciting new product."
    
    "I am extremely pleased that SurModics has teamed with Paragon and Apollo to pursue the development and commercialization of this important technology," said Stuart Williams, Ph.D., Scientific Director at the Cardiovascular Innovation Institute in Louisville, Kentucky. "I have been working for over two decades to understand the mechanisms and specific cell types involved in biomaterial healing and applying that knowledge to improve medical devices. In all those years, I have never seen results in stent applications as impressive as those achieved in SurModics' preclinical studies incorporating the FINALE prohealing coating technology."
    
    SurModics' FINALE prohealing coating technology incorporates extracellular matrix (ECM) proteins designed to improve and accelerate tissue healing of implantable medical devices through the body's own healing mechanisms. Thrombosis, or clotting, remains a significant issue for coronary stents, and is a challenge for which the medical community and the device industry are actively seeking solutions. Incomplete or delayed re-growth of healthy endothelial cells following the placement of stents may be a factor in late thrombosis events. SurModics has teamed with Dr. Williams, a leader in the development of novel cardiovascular implants using tissue engineering techniques, to develop coatings incorporating certain ECM proteins that accelerate the natural healing process following stenting. This approach fosters the re-establishment of a normal endothelial cell layer in the blood vessel. SurModics conducted preclinical studies of FINALE coated stents in collaboration with Dr. Williams and the University of Arizona and generated encouraging results.
    
    Apollo's coronary stent utilizes Paragon's proprietary Inversion Point(TM) technology, resulting in a stent with a significantly lower profile (narrower diameter) when mounted on the balloon of a delivery catheter, improving deliverability and ease of use. Inversion Point resolves a common problem seen in stents made with advanced metals such as cobalt-based alloys; most stents tend to recoil (open slightly) after being mounted on a delivery catheter in the manufacturing process. Inversion Point harnesses the recoil characteristics of advanced metals, creating a stent that remains tightly closed when mounted on a delivery catheter prior to deployment. Using Inversion Point, Apollo has achieved roughly 25 percent lower crossing profile than competing stents without compromising other important stent characteristics such as strength, scaffolding or visibility.
    
    About SurModics, Inc.
    
    SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo(TM) drug delivery polymer matrix as a key component of the first-to-market drug eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products. SurModics is headquartered in Eden Prairie, MN. More information about the company can be found at www.surmodics.com. The content of SurModics' web site is not part of this release or part of any filings the company makes with the SEC.
    
    About Paragon Intellectual Properties, LLC
    
    Paragon Intellectual Properties, LLC was founded in 2004 by Mark C. Bates, M.D., to develop innovative breakthrough solutions to complex medical problems. Headquartered in Charleston, West Virginia, with research and development in Carlsbad, California, Paragon has assembled a team of like-minded clinicians, scientists, engineers and business leaders. Paragon's seven subsidiaries (Apollo Therapeutics, LLC, Biflex Hybrid Stent Systems, LLC, Global Stem Cell Solutions, LLC, Nanotech Catheter Solutions, LLC, Renal Protection Solutions, LLC, Spinal Cord Injury Solutions, LLC and Temporary Intravascular Drug Delivery Systems, LLC) hold fifty-nine issued and pending international or domestic patents. For more information about the company, please visit www.paragon-ip.com.
    
    
12. [verwijderd] 12 juli 2007 23:53

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    pim f - 1 dec 06, 22:58 | Reageer | Quote | Zoek | Aanbevolen: 0
    
    pim f schreef:
    
    Ook het Amerikaanse investeringsfonds SurModles uit Eden Prairie meldt een belang in OctoPlus te hebben verworven; dit belang bedraagt 9,17%. De meldingsplicht voor SurModles ontstond ook 4 oktober 2006.
    
    Beetje overbodig berichtje..... (vandaag op FD.nl)
    
    SurModies meldt belang 9,2% in OctoPlus
    
    AMSTERDAM (FD.nl/Betten) - SurModies Inc. heeft een belang van 9,17% in OctoPlus. Dit blijk uit een melding in het kader van de Wet Melding Zeggenschap in ter beurze genoteerde vennootschappen (WMZ). Op 1 november 2006 is de meldingsplicht ontstaan. Het belang wordt rechtstreeks reeel gehouden. Het stemrecht bedraagt 9,17%. Het belang bestaat uit 1.482.981 gewone aandelen.
    
    De nieuwe wetgeving rond melding zeggenschap en kapitaalbelang in effectenuitgevende instellingen (WMZ 2006) vereist dat bestuurders, en commissarissen alsmede aandeelhouders met een aanmerkelijk belang, per 1 november 2006 hun aandelen opnieuw aanmelden bij de Autoriteit Financiele Markten.